PR Newswire Asia's news > Medical/Pharmaceuticals

 < Previous page   |   Title only   |   Print    Next page > 
     
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
The Phase 3 BiPASS™ study of Illuccix® and Gozellix® for prostate cancer imaging in the pre-biopsy setting has completed enrollment of 350 patients. Telix has positively engaged with the FDA ...
2026-09-02T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Haier Biomedical Highlights Automated Biostorage and Connected Pharma Solutions at ISPE Singapore 2026
Haier Biomedical Accelerates Its Transformation into an Intelligent Biopharmaceutical Infrastructure Platform at ISPE Singapore 2026 ...
2026-09-01T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Haier Biomedical Highlights Automated Biostorage and Connected Pharma Solutions at ISPE Singapore 2026
Haier Biomedical Accelerates Its Transformation into an Intelligent Biopharmaceutical Infrastructure Platform at ISPE Singapore 2026 ...
2026-09-01T    Biotechnology   Medical/Pharmaceuticals 
Suki Named a Transformational Innovation Leader in Ambient Clinical Intelligence by Frost & Sullivan
2026 recognition highlights Suki's innovation, clinical quality and measurable impact as Ambient Clinical Intelligence expands across the enterprise ...
2026-09-01T    Computer Software   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
REJURAN COSMETICS Expands Across Canada with Nationwide Sephora Launch
Premium derma-cosmetic brand from PharmaResearch, the Korean pharmaceutical company behind the globally recognized REJURAN® skin booster available in more than 50 countries, will launch in Sephora ...
2026-09-01T    Biotechnology   Cosmetics & Personal Care   Medical/Pharmaceuticals 
Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development
NANJING, China , Sept. 1, 2026 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced that it has entered into an exclusive global licensing agreement ...
2026-09-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction ...
2026-09-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity ...
2026-09-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel
ROCKVILLE, Md. , Sept. 1, 2026 /PRNewswire/ -- OncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced the ...
2026-09-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Siemens Healthineers showcases its AI-powered technological innovations to redefine healthcare delivery in Southeast Asia
Spotlights how scaling AI and big data can make clinical pathways more efficient Hosts its second ASEAN CEO Summit to drive collaboration amongst healthcare leaders to redefine care delivery in Southeast ...
2026-09-01T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals   Trade show news 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.